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Abstract
Introduction: Oral potentially malignant disorders (OPMDs) are chronic lesions or conditions characterized by a
potential for malignant transformation. Apart from being possible pre-cursors to oral cancer, OPMDs themselves are
usually painful and debilitating conditions having an influence on the quality of life, both in terms of pain and social
disability. Smokeless tobacco (SLT) use is considered a major risk factor for OPMDs. SLT use is a culturally and socially
acceptable habit in South Asia. According to a recent report, 90 % of the SLT burden of the whole world lies in the
South Asian countries of Pakistan, India, Sri Lanka, Bangladesh, Bhutan, Nepal, Afghanistan, and Maldives. This review
aims to assess the association between the use of various SLT products in South Asia and risk of OPMDs.
Methods: This review will focus on epidemiological studies on the use of SLT and risk modification for OPMDs, which
have been carried out in the human population of South Asian countries. Articles reporting estimates of relative risk, e.
g., odds ratio (OR) or relative risk (RR) with their 95 % confidence intervals (CI) for SLT users versus non-users. Articles
reporting data from which these effect estimates can be computed will be included in the review. We will search
MEDLINE, the Science Citation Index (SCI), Scopus, and the Cumulative Index to Nursing and Allied Health Literature
(CINAHL) databases for relevant literature using a combination of keywords and MeSH terms, where applicable.
Appropriate sources of gray literature will also be included in the search. The electronic searches will be supplemented
by a hand search of the bibliographies of the included articles. The included studies will be assessed for their quality
using an established quality assessment tool. All relevant data from the included articles will be recorded in an MS
Excel spread sheet and then transferred to Rev Man 5.3 to carry out a meta-analysis. Heterogeneity among the
estimates will be assessed through the I2 statistic. Sensitivity and subgroup analysis will be carried out to see the effects
of individual or group of studies on the pooled effect estimate. Results of the review will be reported according to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Discussion: This review may have a potential limitation with regard to the designs of the studies included as we
expect that most of the included studies will be of the observational types. We will however try to address this issue
by conducting sensitivity and subgroup analysis of similar quality studies.
Systematic review registration: PROSPERO CRD42015029705.
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Introduction
Oral potentially malignant disorders (OPMD) are
chronic lesions or conditions characterized by a poten-
tial for malignant transformation. More specifically, “It is
a group of disorders of varying etiologies, usually to-
bacco; characterized by mutagen associated, spontaneous
or hereditary alterations or mutations in the genetic ma-
terial of oral epithelial cells with or without clinical and
histo-morphological alterations that may lead to oral
squamous cell carcinoma transformation” [1]. Leukopla-
kia (LP), erythroplakia (EP), submucous fibrosis (SMF),
lichen planus (LP), actinic keratosis (AK), discoid lupus
erythematosus (DLE), and palatal lesions among reverse
smokers constitute OPMD [2]. Rare, inherited syn-
dromes, e.g., xeroderma pigmentosum and Fanconi’s
anemia, and immunodeficiency have also been linked
with the development of oral cancer. In addition, pa-
tients suffering from chronic Graft Versus Host Disease
after stem cell transplantation may also be at a risk of
developing oral cancer [3]. It is generally believed that
the prevalence of OPMD worldwide varies between 1
and 5 % [4]. The potential for malignant transformation
among these conditions vary from less than 1 % to as
high as 36 % [5] and is often influenced by the post-
diagnosis cessation or continuity of the high risk behav-
iors, like tobacco and alcohol use, and clinical interven-
tion [6, 7]. LP, EP, and SMF have a higher potential for
malignant transformation as compared to other [8].
Apart from being possible pre-cursors to oral cancer,
OPMD by themselves are usually painful and debilitating
conditions having an influence on the quality of life,
both in terms of pain and social disability [9].
Smokeless tobacco (SLT) use is considered as a major
risk factor for OPMD [10, 11]. SLT refers to the forms
of tobacco which are used without burning the product.
It is estimated that SLT contains more than 30 carcino-
genic agents [12]. SLT use is a culturally and socially
acceptable habit in South Asia [13] according to a re-
cent WHO report 90 % of the SLT burden of the whole
world lies in the South Asian countries [14]. South Asia
includes Pakistan, India, Sri Lanka, Bangladesh, Bhutan,
Nepal, Afghanistan, and Maldives. Different forms of
SLT products are used in these countries, often dictated
by regional influences [15–18]. The most widely used
products include Betel quid or PAAN with tobacco,
Gutkha, Naswar, Chaini, Misri, and chewable tobacco
leaves. The carcinogenic agents in tobacco act by indu-
cing changes at both genetic level and locally by provid-
ing a conducive local environment for hyperplastic
transformation of the buccal cells [19].
We conducted pre-review scoping searches to identify
the current state of literature on OPMDS, specifically
systematic reviews on OPMDs and literature pertaining
to the risk of OPMDs associated with the use of SLT.
The majority of recent systematic reviews on SLT use
have focused on the link between SLT and oral cancer
[13, 20, 21], but we identified a knowledge gap with re-
gard to the effects of SLT use and development of
OPMDs, particularly in the context of South Asia. We
therefore aim to conduct a systematic review on the re-
lationship between SLT and OPMDs to provide evidence
which would be beneficial for the scientific community,
the tobacco industry, patients, and the general public. It
could also help inform the tobacco control policies in
South Asia, which have been shown to be underper-




The objective of this study is to quantify the risk of de-
veloping OPMDs associated with the use of SLT (ever
versus never users) by pooling effect estimates from epi-
demiological studies carried out in South Asia among
both males and females of any age group.
Specific
 To assess the individual risk of different forms of
SLT use associated with the development of any
OPMD
 To assess the individual risk of development of
different OPMDs with the use of SLT
 To assess the risk of developing OPMDs with the
use of SLT separately among men and women
 To explore exposure-response relationships in terms
of duration and intensity of use of SLT products and
the risk of development of OPMDs
 To stratify the risk estimates for individual countries
and/or if applicable regions
 To calculate the population attributable fraction
(PAF) associated with the use of SLT and
development of OPMDs
Methods
This protocol follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis Protocols
(PRISMA-P) 2015, guidelines. The corresponding
checklist is provided in Additional file 1.
Eligibility criteria
Study design
This review will focus on epidemiological studies investi-
gating the use of SLT and risk modification for OPMDs,
which have been carried out in the human population of
South Asian countries. Although data generated by ex-
perimental research designs, e.g., randomized clinical or
community trials, are considered the gold standard, we
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expect that our search will mostly yield studies with an
observational design, due to the inherent ethical issues
regarding the potential harm of using SLT. This has
been further substantiated through our preliminary
scoping searches for the review and a perusal of previous
reviews on SLT and oral cancer, where most of the pub-
lished literature involves observational studies, mostly
case-control and cohort designs [13, 20, 21]. However,
we will not limit our search to observational designs and
will also include experimental studies satisfying our
inclusion criteria. Laboratory-based genetic epidemio-
logical studies will not be eligible for inclusion.
Participants/population
Studies carried out among both males and females irre-
spective of age, socio-economic, physical, or dental sta-
tus, who are residents of the countries of South Asia,
will be included in the review. For studies to be eligible
for the review, the reported cases must have been ascer-
tained as having an OPMD through medical and/or
histological records. Studies carried out among expatri-
ate populations of South Asia will not be included, as
there may be large differences between tobacco habits
and products among the resident populations and the
expatriate ones. Studies focusing on animals will not be
included.
Exposure
Studies in which exposure to an SLT product has been
ascertained through written records, e.g., medical his-
tory, structured interviews, or written self-reports will be
included. For the purpose of this review, an “ever” ex-
posed participant is defined as someone who might have
used an SLT product at least once in life. Exposure will
be quantified in years and daily frequencies for the as-
sessment of the exposure-response relationship between
OPMD and SLT. Only the studies reporting daily fre-
quencies and total duration of exposure or reporting
data to calculate these will be eligible for the exposure-
response analysis. Since SLT products in South Asia are
often produced unregulated [22], it is difficult to quan-
tify the intensity of exposure and hence intensity will
not be used as an inclusion/exclusion criteria for this re-
view. Studies which exposure of interest is areca nut
alone or betel quid without added tobacco, although
often investigated together along with other SLT prod-
ucts, will not be eligible for this review as these might
contribute to increased heterogeneity because of differ-
ences in carcinogenic potential among these and SLT
products.
Comparator(s)/control
For case-control studies, the control group must have
included subjects who have no history of OPMDs,
irrespective of their use of SLT. Matching for age, sex,
and other potential confounders will not be used as in-
clusion criteria, in order to include maximum studies.
The source of controls, i.e., hospital or community-
based will not affect the inclusion/exclusion of a study
for the review. For cohort studies, the use of a com-
parator will not be a requirement for inclusion.
Outcome
Studies which report an OPMD as the, or one of the,
primary or secondary outcome/s will be included in the
review. Studies where cases were recruited after verifica-
tion through a medical record or a laboratory report or
a clinical examination by a qualified person will be
included. Articles reporting estimates of relative risk,
e.g., odds ratio (OR) or relative risk (RR) with their 95 %
confidence intervals (CI) for SLT users versus non-users
(ever versus never) as well as those reporting data from
which these effect estimates can be computed will be
included in the review. In case there is a potentially
eligible study, where effect estimates or data to calculate
them is not reported in the manuscript, the authors of
the manuscript will be requested to provide the relevant
data.
Follow-up
In order to include maximum studies, the length of
follow-up will not be used as an inclusion/exclusion
criterion for studies. If applicable, studies having similar
lengths of follow-up will be pooled together in a sub-
group analysis.
Setting
Studies will be included irrespective of the study setting,
i.e., hospital-based (private and public) or community-
based. The only exception will be laboratory based gen-
etic epidemiology studies.
Language
No filters will be used during the search process and
hence studies published in any language will be eligible
for inclusion in this review.
Search methods
We will search MEDLINE, the Science Citation Index
(SCI), Scopus, and Cumulative Index to Nursing and Al-
lied Health Literature (CINAHL) databases for relevant
literature. A combination of keywords and MeSH terms,
where applicable, will be used for the electronic search. A
detailed search strategy, developed for this review by an
information sciences specialist (LC), is provided in
Additional file 2. In order to include all relevant literature,
no filters will be used during the electronic search. The
electronic search will be supplemented by a hand search
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of the bibliographies of selected articles and previously
published narrative reviews. Efforts will be made to find
non-indexed and gray literature pertaining to the topic via
an electronic search of regional electronic research reposi-
tories especially the World Health Organization’s regional
and global Index Medicus, which often contain local
literature not indexed with the main stream research indi-
ces (search strategy provided as Additional file 3). Internet
search engines, e.g., Google Scholar will also be used to
identify any relevant literature. Search strategy for these
databases is provided in Additional file 4.
Selection of studies
One author (LC) will create and run the search query
in the databases and export the results to reference
management software EndNote [23]. Duplicate records
will then be removed via the duplicate search function
of the reference management software. Two authors
(SK and SR) will then independently go through the
titles and abstracts of all the records and select the
studies relevant to the review. The authors will com-
pare their results with each other and in cases of dis-
agreement, a third author (ZK) will be contacted to
resolve the issue, with his/her opinion being decisive.
The authors of the original articles may be contacted to
clarify issues regarding eligibility. Full texts of the
selected studies will be obtained and will be independ-
ently screened for inclusion or exclusion in the final re-
view by two authors (SK and SR). The list of selected
studies will then be compared and any disagreements
will be resolved through a third author (ZK). Finally,
the bibliographies of the selected studies will be
screened for any relevant studies that might have been
missed during the search process. The selection process
for the studies will be presented using a flowchart.
Assessment of the quality of included studies
All selected studies will be assessed for their quality using
the National Collaborating Centre for Methods and Tools,
McMaster University’s “Effective Public Health Practice
Project Quality Assessment Tool for Quantitative Studies”
[24]. The authors have previous experience with this tool
[13], and in our opinion, it is well suited to the quality
assessment of analytical study designs. Studies will be
ranked as “strong,” “moderate,” or “weak” based on six
parameters, i.e., selection bias, study design, confounding,
blinding, data collection methods, and withdrawals and
dropouts. In case there are eligible randomized studies, we
will use the Cochrane Collaboration tool for assessing the
risk of bias, to assess the quality of those studies. Quality
assessment will be carried out by (SK and SR) independ-
ently. Any disagreements on the quality of the studies will
be resolved in the presence of a third author (ZK).
Data extraction and management
Data regarding study type, publication year, authors
name, place of study, sample size, type/s of exposure,
exposure frequency and duration, and outcome/s and
effect estimates (OR and RR) will be extracted inde-
pendently by two authors (ZK and SK) and will be
recorded onto a pre-designed data extraction spread-
sheet (provided in Additional files 5 and 6).
Sample size of the studies where the only outcome is
an OPMD will be extracted as such, i.e., the numbers re-
ported in the study. In case there are multiple outcomes,
e.g., oral cancer and OPMDs, then the oral cancer cases
will be excluded from the sample size and only the cases
with OPMD will be reported. Where applicable effect es-
timates for men and women will be recorded separately
in addition to the overall effect estimate.
Based on original reporting in the included studies,
the exposure/s (SLT) will be classified during data ex-
traction as Gutkha, Betel quid with tobacco, areca nut
with tobacco, chewing tobacco leaves or others. The
term “any SLT” will be used for those exposures where
the type of SLT is not mentioned in the included studies.
Where applicable and depending on the availability of
data, a single study might be treated as two or multiple
studies if it reports separate risk of OPMD with the use
two or more SLT types. Both adjusted (for smoking and
alcohol) and crude effect estimates will be recorded.
The outcome for each study will be recorded as one of
leukoplakia, erythroplakia, submucous fibrosis, multiple
OPMDs or others depending on how they are reported in
the included studies. In case the original study has not
differentiated between the OPMD types than the term
“All OPMD,” will be used to record the outcome for that
study. If a study reports separate effect estimates for differ-
ent types of OPMDs than it will be treated as two or more
separate studies corresponding to the related outcome.
We will not address co-morbidities and/or secondary
outcomes for this review.
Follow up for cohort and trials will be recorded as
mean duration of follow up in years.
The individual data recording spreadsheet from each
author will then be compared in the presence of a
third author (OE), and if there are any differences, the
opinion of the third author will be decisive. The third
author (OE) can also decide to contact the authors of
the included articles to resolve or further clarify issues
regarding the data or for additional information. ORs
and RRs will be calculated for studies which do not
report an OR or RR but have enough data for their
calculation. Efforts will be made to calculate an
adjusted effect estimate; however, a crude estimate will
be used if the available data is insufficient to calculate
an adjusted one. The data will then be entered into
RevMan 5.3. by ZK.
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Meta, subgroup, and sensitivity analysis
Data synthesis
Each outcome will be combined and calculated using
the statistical software RevMan 5.3, according to the
statistical guidelines referenced in the current version of
the “Cochrane Handbook for Systematic Reviews of
Interventions” [25]. We will pool effect estimates from
those included studies to calculate a meta-risk estimate
for OPMDs with the use of SLT products using a
random effects model. We will use the inverse variance
method to account for the potential inconsistencies be-
tween the studies. Standard errors for the effect esti-
mates will be calculated from the given confidence
intervals after conversion to a log scale. We will carry
out quantitative data synthesis if we have one represen-
tative study from at least three countries of South Asia.
Previous systematic reviews from South Asia on SLT and
oral cancer [13, 20, 21] have carried out meta-analysis
despite the presence of very high inconsistency I2 >75 %
to provide a meta-risk estimate, because the magnitude
of the pooled estimates are often so high that even if we
consider the effects of heterogeneity, a causal link be-
tween the two can still be suspected. We expect a simi-
lar or an even higher magnitude of risk for OPMDs with
the use of SLT products in South Asia and therefore will
carry out a quantitative synthesis irrespective of the het-
erogeneity, publication bias and quality of the included
studies. The readers though will be informed about the
magnitude of the heterogeneity with every pooled effect
estimate and the quality of studies, so they could inter-
pret the results in the light of these findings.
The primary analysis will focus on “never versus ever”
users of SLT products. We will also calculate individual
meta-risk estimates for each subtype of OPMD and also
perform a stratified analysis based on the type of SLT
products. If feasible other subgroup analysis may include
male versus female, stratification by country, as well as
the relationship between the magnitude and intensity
(dose-response) of the exposure and the outcome. Sensi-
tivity analysis may include inclusion or exclusion of
studies with different quality, studies reporting a very
high or a very low effect estimate, studies with very
large, or very small sample size etc. Reporting bias will
be assessed using a visual funnel plot. The analysis will
be carried out in RevMan 5.
Missing data
In case there are missing data, the original authors of
the study will be contacted, to obtain the relevant miss-
ing data. If missing data cannot be obtained, an imput-
ation method will be used. We will use sensitivity
analysis to assess the impact of inclusion of studies
which do not report an effect estimate and it has been
calculated by the authors or with missing data.
Assessment of heterogeneity
Heterogeneity will be assessed by visually inspecting for-
est plots. The I2 statistic will be calculated for the quan-
tification of inconsistencies and assessment of the effects
of heterogeneity in the pooled analysis. A meta-analysis
will be performed irrespective of the presence or absence
of heterogeneity or a high I2 value. Causes of heterogen-
eity (if present) will be assessed through a subgroup and
sensitivity analysis. The cause of heterogeneity may be a
difference in sample size between the studies, retrospect-
ive versus prospective study designs, difference in back-
ground risk among the populations of different
countries, representation of females (lower background
risk) in the study sample, length of follow up, Inter and
intra-country differences between the composition of
SLT products, presence or absence of confounders and
exposure quantification differences.
The subgroup analysis may involve stratified analysis
by country, gender, length of follow-up, adjustment for
smoking and alcohol, type of SLT, type of OPMD, and
exposure-response categories. Sensitivity analysis may
involve dropping of studies with a low quality and stud-
ies where crude effect estimates were reported or calcu-
lated by the authors. If applicable and depending on the
availability of data, meta-regression will be performed to
account for the effect of co-exposures and other
confounders.
Assessment of meta-bias(es)
If available, protocols for randomized studies will be
accessed and compared with the included study to assess
selective reporting of outcomes. However, we expect that
analytical studies will pre-dominantly form the core of
our included studies and these usually do not have pub-
lished protocols. We will run both the fixed effect model
and the random effects model to assess the possible
presence of small sample bias in the included studies.
We will further assess publication bias through funnel
plots (if the number of available studies is equal to or
more than 10). This will be carried out by ZK and OE.
Confidence in cumulative evidence
The Grading of Recommendations Assessment, Devel-
opment and Evaluation Working Group methodology
will be used to assess the quality of the cumulative evi-
dence. The quality of evidence will be assessed on the
basis of risk of bias, consistency, directness, precision,
and publication bias by two authors (ZK and FSZ).
Differences between protocol and review
If applicable, the differences between the published
protocol and the review, and the circumstances and rea-
sons, which necessitated these changes will be disclosed
to the readers of the review.
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Discussion
This review will identify and synthesize evidence regard-
ing the use of SLT products and the risk of developing
OPMDs in the context of South Asia. To the best of our
knowledge, this is the first systematic review which will
address the issue of SLT use and the risk of development
of OPMDs. We therefore, hope that our findings will
help inform tobacco control policies in the region as
well as empowering health professionals and general
public with evidence regarding the deleterious effects of
SLT use and the risk of developing OPMDs associated
with SLT.
The potential inclusion of pre-dominantly observa-
tional studies in the review may raise concerns over the
quality of the evidence, as these designs are susceptible
to bias(es). However, due to ethical reasons, it is not
possible to carry out an experimental study to assess the
risks associated with SLT use, and hence, we have to rely
on observational data to estimate the risk estimates for
OPMDs associated with SLT use. We are aware of this
limitation and will aim to minimize the effects of both
intra and extra-study factors which might influence the
cumulative incidence.
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